MET and ovarian cancer: Beside TP53 mutations (in total 64%; 81% in HGSC) and BRCA mutations (BRCA 1 = 11%; BRCA 2 = 2%), the majority (66.6%) of detected genetic alterations (CDH1, FOXL2, MET, RET, KIT, MSH6, FBXW7, PPP2R1A, PITCH1, ERBB3, APC, ATM, TERT, NF1, MYCN and ABL1) were mutations of low frequency (<10%) and mutually exclusive, contributing to our understanding of the heterogeneity of ovarian cancer and its rather low mutational burden [35,36].